Now, it is being tested in HER2 positive MBC with PIK3CA mutations in multiple clinical trials and emerging results will guide us to deal with HER2 positive breast cancer with PIK3CA mutations (ClinicalTrials.gov Identifier: NCT05063786, NCT05230810, NCT04208178). This evidence concerns the gene ERBB2 and breast carcinoma.